Skip to Main Content

Paper Details

The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients.
Open Res Eur
0
2022
Author NameAffiliation
Andrew J LoteryUniversity of Southampton
Frank G Holz
Frank G HolzUniversity of Bonn
Steffen Schmitz-Valckenberg
Steffen Schmitz-ValckenbergUniversity of Bonn
Steffen Schmitz-ValckenbergUniversity of Utah
Katarina StinglUniversity Eye Hospital, Center for Ophthalmology, Institute for Ophthalmic Research, University of Tubingen
Katarina StinglCenter for Rare Eye Diseases, University of Tubingen
Carel B HoyngRadboud University Nijmegen Medical Centre
Carel B HoyngDonders Institute for Brain
  • 1 - 10

Datasets

Release 1.2